Latest News

An overview of the FDA’s draft guidance on MRD as a clinical trial end point, with expert insight on what it means for drug development in multiple myeloma.

Discover how AI accelerates precision cancer care, streamlines trials, and tackles bias and liability—what oncologists need to know now.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

Durvalumab boosts survival in limited-stage SCLC, yet U.S. costs miss value thresholds—fueling urgent debates on access and pricing.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

New Uniphar deal widens European managed-access to Lymphir for relapsed CTCL, spotlighting targeted immunotherapy and manageable early-cycle risks.

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed how recent trial findings are affecting their treatment of newly diagnosed multiple myeloma.

Cancer survival hits 70% as early screening and immunotherapy advance—yet survivorship needs and Indigenous disparities demand urgent action.

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the EXCALIBER-RRMM trial.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant, thus closing the access gap.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

Dr Manmeet Ahluwalia explores how precision oncology and targeted therapies are transforming brain metastases care, extending survival from months to years.

Cancer breakthroughs surge, but trials and novel therapies stay out of reach for many. See how community care, policy, and design can close gaps.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.